Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PARP”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT02740712
What this trial is testing

Pharmacokinetic Drug-Drug Interaction Study of Rucaparib

Who this might be right for
Neoplasms
pharmaand GmbH 17
Large-scale testing (Phase 3)Active Not RecruitingNCT03522246
What this trial is testing

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Who this might be right for
Epithelial Ovarian CancerPrimary PeritonealFallopian Tube Cancer+4 more
pharmaand GmbH 1,097
Testing effectiveness (Phase 2)Study completedNCT03427814
What this trial is testing

Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer

Who this might be right for
Advanced or Inoperable Gastric Cancer
BeiGene 136
Testing effectiveness (Phase 2)Study completedNCT01560104
What this trial is testing

A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

Who this might be right for
Non-Small -Cell Lung Cancer
AbbVie (prior sponsor, Abbott) 160
Testing effectiveness (Phase 2)Study completedNCT01891344
What this trial is testing

Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)

Who this might be right for
Ovarian CancerEpithelial Ovarian CancerFallopian Tube Cancer+1 more
pharmaand GmbH 491
Testing effectiveness (Phase 2)Ended earlyNCT03824704
What this trial is testing

Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)

Who this might be right for
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma+2 more
pharmaand GmbH 1
Testing effectiveness (Phase 2)Looking for participantsNCT06074692
What this trial is testing

PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)

Who this might be right for
SarcomaSarcoma,Soft TissueSarcoma of Bone
Ruijin Hospital 86
Not applicableEnded earlyNCT07000344
What this trial is testing

Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor

Who this might be right for
Ovarian Cancer
Peking Union Medical College Hospital 5
Testing effectiveness (Phase 2)Study completedNCT00628251
What this trial is testing

Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer

Who this might be right for
Ovarian Neoplasms
AstraZeneca 97
Early research (Phase 1)Study completedNCT01623349
What this trial is testing

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

Who this might be right for
Ovarian CancerBreast Cancer
Dana-Farber Cancer Institute 118
Not applicableLooking for participantsNCT06710548
What this trial is testing

REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors

Who this might be right for
Ovarian CancerAdvanced Ovarian CarcinomaFallopian Tube Carcinoma+4 more
Dana-Farber Cancer Institute 240
Testing effectiveness (Phase 2)Study completedNCT02042378
What this trial is testing

Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation

Who this might be right for
Pancreatic CancerPancreatic Ductal Adenocarcinoma
pharmaand GmbH 19
Testing effectiveness (Phase 2)Looking for participantsNCT05269316
What this trial is testing

Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

Who this might be right for
Solid TumorAdvanced Solid Tumor
Impact Therapeutics, Inc. 61
Testing effectiveness (Phase 2)Study completedNCT00912743
What this trial is testing

Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status

Who this might be right for
Colorectal Cancer
AstraZeneca 33
Testing effectiveness (Phase 2)Active Not RecruitingNCT02484404
What this trial is testing

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

Who this might be right for
Colorectal NeoplasmsBreast Neoplasms
National Cancer Institute (NCI) 268
Early research (Phase 1)Study completedNCT00526617
What this trial is testing

A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients

Who this might be right for
Non-hematologic MalignanciesMetastatic MelanomaBreast Cancer+4 more
AbbVie 41
Testing effectiveness (Phase 2)Study completedNCT00813956
What this trial is testing

Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Sanofi 80
Testing effectiveness (Phase 2)Study completedNCT04110028
What this trial is testing

Nicotinamide Riboside in Hospitalized Patients

Who this might be right for
InflammationAcute Illness
Oslo University Hospital 57
Testing effectiveness (Phase 2)Looking for participantsNCT07673341
What this trial is testing

[18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma

Who this might be right for
Cholangiocarcinoma
University of Washington 22
Large-scale testing (Phase 3)Ended earlyNCT03642132
What this trial is testing

Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)

Who this might be right for
Ovarian Cancer
Pfizer 79
Next Page